Product Information
SAVELLA 12.5 MG TABLET is a brand product labeled by Allergan, Inc., priced at $8.1640 per EA under NDC 00456151260. Its NADAC has been published 669 times since Nov 28, 2013.
FDA first approved this application on Jan 14, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5 mg/1
Manufacturer
Allergan, Inc.NDC
00456151260
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MILNACIPRAN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA022256FDA Approved
1/14/2009
TE Code
AB
On Market Since
4/17/2009
Pharmacological Classes
Price Statistics
The NADAC for SAVELLA 12.5 MG TABLET has been published 669 times since Nov 28, 2013, and over the history we have for it it has risen 199.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.1640 per EA |
|---|---|
| All-time high | $8.1770 (Jul 16, 2025) |
| All-time low | $2.5652 (Mar 19, 2014) |
| 52-week high | $8.1668 |
| 52-week low | $8.1479 |
| Median price | $6.3860 |
| Average price | $6.0338 |
| Largest weekly change | +9.9% (Apr 16, 2014) |
| Weeks tracked | 669 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the milnacipran hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
milnacipran hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAVELLA 12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAVELLA 12.5 MG TABLET, manufactured by Allergan, Inc., is $8.1640 per EA (NDC 00456151260), effective Sep 30, 2026.
How has the price of SAVELLA 12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAVELLA 12.5 MG TABLET has risen 199.1%. It has been tracked across 669 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SAVELLA 12.5 MG TABLET?
Since Nov 28, 2013, the NADAC for SAVELLA 12.5 MG TABLET has ranged from a low of $2.5652 (Mar 19, 2014) to a high of $8.1770 (Jul 16, 2025), with a median of $6.3860 per EA.
Are there cheaper alternatives to SAVELLA 12.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SAVELLA 12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SAVELLA 12.5 MG TABLET?
SAVELLA 12.5 MG TABLET (NDC 00456151260) is labeled by Allergan, Inc., and CMS classifies it as a brand product.